urlscan.io logo urlscan.io
SecurityTrails logo

endpts.com Open in urlscan Pro
99.86.91.105  Public Scan

Back to summary
Submitted URL: https://e.endpointsnews.com/t/t-l-vthhuc-wdkidkilh-s/
Effective URL: https://endpts.com/verve-shares-first-base-editing-results-in-patients-with-hefh/?utm_medium=email&utm_campaign=184...
Submission: On November 13 via api from US — Scanned from DE

Form analysis 1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Health Tech
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN



November 12, 2023 03:30 PM ESTUpdated 1 hour ago
R&D


VERVE SHARES FIRST BASE EDIT­ING RE­SULTS IN HU­MANS, SUG­GEST­ING THER­A­PY CAN
LOW­ER CHO­LES­TEROL IN PA­TIENTS WITH GE­NET­IC CON­DI­TION


LEI LEI WU

NEWS REPORTER

PHILADEL­PHIA — Verve Ther­a­peu­tics’ next-gen­er­a­tion gene edit­ing
treat­ment low­ered cho­les­terol lev­els in a hand­ful of pa­tients with
het­erozy­gous fa­mil­ial hy­per­c­ho­les­terolemia, mark­ing the first time
that base edit­ing has been used to di­rect­ly al­ter DNA in hu­mans.

The ear­ly Phase I da­ta, pre­sent­ed Sun­day at the Amer­i­can Heart
As­so­ci­a­tion’s sci­en­tif­ic meet­ing, give a glimpse at how the in
vi­vo treat­ment works in peo­ple who have been di­ag­nosed with the ge­net­ic
dis­or­der that caus­es high cho­les­terol and of­ten heart dis­ease at an
ear­ly age.


UNLOCK THIS ARTICLE INSTANTLY BY BECOMING A FREE SUBSCRIBER.

You’ll get access to free articles each month, plus you can customize what
newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER


TRENDING NOW


AF­TER SHOW­ING WE­GOVY CUT CAR­DIO­VAS­CU­LAR RISK BY 20%, RE­SULTS DE­TAIL
IM­PACT ON DEATH AND HEART FAIL­URE


FIRST DA­TA FOR LIL­LY'S RNA TREAT­MENT FOR HEART DIS­EASE POINT TO LONG-TERM
DURA­BIL­I­TY IN TINY GROUP OF PA­TIENTS


AL­NY­LAM’S LONGER-TERM RNAI TREAT­MENT LOW­ERS BLOOD PRES­SURE IN MID-STAGE
STUDY


AS­TRAZENECA PRE­PARES TO LIVE WITH THE IRA, SHIFT­ING FO­CUS OF AR­GU­MENTS TO
OR­PHAN DRUG CHANGES


UCB, ELI LIL­LY-BACKED VIA­NAUTIS RAIS­ES $25M IN SE­RIES A TO DE­VEL­OP
GE­NET­IC NANOMED­I­CINES

sponsored


CLIN­I­CAL STUD­IES IN JAPAN TO­DAY: AN­OTH­ER LOOK AT THE WORLD’S
SEC­OND-LARGEST PRE­SCRIP­TION DRUG MAR­KET IN A ...

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Health Tech
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2023

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


EMAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET

SIGN UP FOR FREE TO READ A LIMITED NUMBER OF ARTICLES EACH MONTH.

ABOUT YOU







NEWSLETTER INTERESTS

PICK WHAT NEWSLETTERS GET DELIVERED TO YOUR INBOX EACH WEEK.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 2 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET



Healthcare

ENDPOINTS HEALTH TECH Coming soon


INSTANT SIGN UP

Want unlimited access? Sign up for a premium subscription plan.